TME Pharma
Pharmaceutical Manufacturing • 
Berlin, Berlin, Germany • 11-20 Employees
Company overview
| Headquarters | Max-Dohrn-Str. 8-10, Berlin, 10589, DE |
| Phone number | +49307262470 |
| Website | |
| NAICS | 3254 |
| Founded | 1998 |
| Employees | 11-20 |
| Socials |
Key Contacts at TME Pharma
Anna Frömming
Director Translational Research
Anna Frömming
Director Translational Research
TME Pharma Email Formats
TME Pharma uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@noxxon.com), used 22.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@noxxon.com | 44.4% |
{first name}{last name} | johndoe@noxxon.net | 44.4% |
{last name} | doe@noxxon.net | 11.1% |
About TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.
TME Pharma revenue & valuation
| Annual revenue | $1,197,770 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $3,900,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
TME Pharma has 6 employees across 5 departments.
Departments
Number of employees
Funding Data
TME Pharma has never raised funding before.
TME Pharma Tech Stack
Discover the technologies and tools that power TME Pharma's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Web servers
CMS
JavaScript libraries
Tag managers
Programming languages
Hosting
UI frameworks
Analytics
Miscellaneous
United States
Sweden
Canada
United Kingdom
FranceFrequently asked questions
4.8
40,000 users
